Axel Hoos
GlaxoSmithKline (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Immune cells in cancer, Melanoma and MAPK Pathways
Most-Cited Works
- → Improved Survival with Ipilimumab in Patients with Metastatic Melanoma(2010)15,035 cited
- → Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma(2011)4,451 cited
- → Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria(2009)3,202 cited
- → Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial(2015)1,248 cited
- → Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study(2009)1,182 cited
- → Design of amidobenzimidazole STING receptor agonists with systemic activity(2018)822 cited
- → Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study(2019)777 cited
- → Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations(2016)602 cited
- → Analysis of the Prognostic Significance of Microscopic Margins in 2,084 Localized Primary Adult Soft Tissue Sarcomas(2002)582 cited
- p63 expression profiles in human normal and tumor tissues.(2002)